Molecular targeted therapy for hepatocellular carcinoma / 医学研究生学报

ABSTRACT

Hepatocellular carcinoma (HCC) is the fourth malignant tumor with the third mortality rate in China. Most patients have lost their chance of surgery at the time of diagnosis and are required to receive systemic treatment. The molecular targeted agent sorafenib has brought revolutionary progress for the treatment of advanced liver cancer. The latest diagnosis and treatment guidelines for hepatocellular carcinoma in China also recommend sorafenib as the first choice for systematic treatment of advanced liver cancer. With the gradual deepening of our understanding of the biology of hepatocellular carcinoma, the continuous accumulation of drug experience and the increasing perfection of clinical research system, molecular targeted agents and effective drug regimens for advanced hepatocellular carcinoma will appear in succession. This article reviews the progress in this field.